ShredStack™
Improve body composition, metabolic flexibility and appetite control, the foundation of medical weight loss. ShredStack pairs GLP-1 therapy with mitochondrial and metabolic support so fat loss is sustainable rather than crash-driven.
- The metabolic core. And it is one medicine, not two. Your clinician prescribes a single GLP-1 agent: semaglutide or tirzepatide (both approved), or, where clinically appropriate and permitted, the investigational triple agonist retatrutide. These are alternatives chosen for you; two GLP-1 medicines are never run together. The chosen agent slows gastric emptying, curbs appetite and improves insulin sensitivity for steady, supervised weight loss, with the dose escalated gradually.
- Mitochondrial-derived peptide proposed to activate AMPK and act as an exercise mimetic for glucose use and fat oxidation. Evidence is early and not established in humans.
- NAD⁺ CoenzymeSupports mitochondrial metabolic pathways and cellular energy as the body shifts into fat loss.
Best for
- Medical weight loss and appetite control
- Metabolic syndrome / insulin resistance
- Plateaus on single-agent GLP-1
- Body recomposition alongside training
How it works
GLP-1 and multi-receptor agonists work centrally to reduce appetite and slow digestion, while improving how the body handles glucose and insulin. Layering MOTS-c and NAD⁺ supports the mitochondria so the body burns fat for energy more efficiently as intake drops. The aim is gradual, monitored loss with muscle preserved, not a crash diet.
What to expect
GLP-1 therapy has strong evidence and can produce significant results, but it is honest to say it works as ongoing therapy, not a one-time cure: weight is commonly regained if it is stopped. To protect lean muscle, it should be paired with adequate protein and resistance training. It is not suitable for everyone. For example, those with a personal or family history of medullary thyroid cancer or MEN2, or who are pregnant. Doses are escalated slowly to manage tolerability; appetite often drops within the first weeks, with body-composition change building over months. Individual results vary, and your clinician confirms suitability.
Who it's for / not for
- Adults pursuing medically supervised weight loss
- Insulin resistance or metabolic syndrome
- Not during pregnancy or breastfeeding
- Caution with thyroid (MTC/MEN2) history, pancreatitis or significant GI disease
- Eligibility, lab work and cardiovascular assessment are confirmed by your clinician